ErbB2+ metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country. [electronic resource]
Producer: 20161010Description: 270-80 p. digitalISSN:- 2539-3596
- Adult
- Aged
- Antimetabolites, Antineoplastic -- economics
- Antineoplastic Combined Chemotherapy Protocols -- economics
- Breast Neoplasms -- drug therapy
- Capecitabine -- administration & dosage
- Carcinoma, Ductal, Breast -- drug therapy
- Colombia
- Cost-Benefit Analysis
- Developing Countries
- Disease Progression
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Female
- Health Expenditures
- Humans
- Insurance, Health, Reimbursement
- Lapatinib
- Markov Chains
- Middle Aged
- Prescription Fees
- Quinazolines -- administration & dosage
- Receptor, ErbB-2 -- analysis
- Taxoids -- administration & dosage
- Trastuzumab -- administration & dosage
- Vinblastine -- administration & dosage
- Vinorelbine
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.